This course was last updated on
December 20, 2016
CME credit has expired.


Stewart J. Tepper, MD, analyzes 4 key studies and provides his perspectives on the clinical implications and potential application of CGRPs as targeted treatment for migraines.

Listen to summaries of 4 recently published studies.

Compare your knowledge against your peers.

Content Areas

  • Ubrogepant
  • CGRP monoclonal antibodies
  • AMG 334
  • TEV-48125
  • ALD403

Target Audience

This activity was developed for headache specialists, neurologists, primary care physicians and other health care professionals who have an interest in research and treatment advances in migraine.

This activity is supported by educational funding provided by Amgen.


Stewart J. Tepper, MD

Stewart J. Tepper, MD

Professor of Neurology
Geisel School of Medicine at Dartmouth
Hanover, New Hampshire

Enter your information to begin.
CME Credit
Available Credit: 1.00 AMA PRA Category 1 Credit™.
Opens: December 20, 2016
Expires: December 19, 2017
Target Audience: Headache Specialists
Primary Care Physicians
Other Health Care Providers